Oral glycomacropeptide increased filaggrin, beta-defensin 2, and cathelicidin in eczema-damaged skin while preventing bacterial colonization and modifying gut bacteria.
Gut-to-skinoral GMP improved skin barrier, boosted antimicrobial peptides, and modified gut bacteria — demonstrating gut-skin axis treatment potential
What the researchers found
Glycomacropeptide (GMP) given by mouth significantly increased filaggrin, beta-defensin 2, and cathelicidin expression in damaged skin. These are proteins critical for maintaining the skin barrier and fighting off infections.
GMP also strongly reduced epidermal thickening and IFN-gamma expression in damaged skin. This means it calmed the inflammatory response driving the eczema-like condition.
On the microbiome side, GMP prevented Staphylococcus aureus colonization of the skin, which is a major trigger for eczema flares. In the gut, GMP boosted Bifidobacterium levels and increased short-chain fatty acids (acetic acid and butyric acid), especially when given before eczema was induced.
Why it matters
Eczema affects millions of people, and maintaining the skin barrier is one of the most important parts of treatment. This study shows a food-derived peptide could help restore that barrier from the inside out, working through the gut-skin connection.
The fact that GMP worked both preventively and as treatment, and that it blocked S. aureus colonization, makes it especially interesting for people who deal with recurring eczema flares.
The numbers in context
Increased filaggrin, beta-defensin 2, cathelicidin; reduced epidermal thickening and IFN-gamma; prevented S. aureus colonization; boosted Bifidobacterium and fecal SCFAs
How the study worked
Researchers induced eczema-like dermatitis on rat skin using repeated applications of DNCB (a chemical irritant). Rats received oral GMP either before or after eczema induction. They measured skin proteins by immunoblot and immunohistochemistry, skin thickness by histochemistry, IFN-gamma and microbiota by PCR, and fecal short-chain fatty acids by gas chromatography.
Who was studied
Rats with chemically induced eczema-like dermatitis
What this study cannot tell us
This was an animal study using chemically induced eczema, which does not perfectly mimic human atopic dermatitis. The doses used in rats may not translate directly to human dosing.
The study did not measure how long the benefits lasted after stopping GMP treatment.
How to read the evidence
Preliminary evidence from a rat model. Multiple endpoints consistent but human eczema differs from chemically induced dermatitis.
When this study was published
Published in 2020. Gut-skin axis research continues to expand with increasing interest in dietary interventions for skin conditions.
The bigger picture
Eczema affects millions and skin barrier restoration is central to treatment. A food-derived peptide that works from the inside — through the gut-skin axis — could complement topical treatments and reduce the need for steroids and immunosuppressants.
Questions still open
- Would GMP help human eczema patients?
- What is the optimal dose and duration for skin barrier effects?
- Does the gut-skin axis mechanism work through specific bacterial strains?
Common questions
What is glycomacropeptide?
Can eating or drinking GMP help eczema?
Read the original research
Protective Effect of Glycomacropeptide on the Atopic Dermatitis-Like Dysfunctional Skin Barrier in Rats.
Journal of medicinal food, 23(11), 1216-1224
Citation
Jiménez, Mariela; Muñoz, Fabiola C; Cervantes-García, Daniel; Cervantes, Maritza M; Hernández-Mercado, Alicia; Barrón-García, Berenice; Moreno Hernández-Duque, José L; Rodríguez-Carlos, Adrián; Rivas-Santiago, Bruno; Salinas, Eva. (2020). Protective Effect of Glycomacropeptide on the Atopic Dermatitis-Like Dysfunctional Skin Barrier in Rats.. Journal of medicinal food, 23(11), 1216-1224. https://doi.org/10.1089/jmf.2019.0247